Roche : new up leg in sight ?
Nicolas Suiffet June 19, 2020 8:33 AM
Roche, the pharmaceutical giant, said a phase 3 study, evaluating its ipatasertib in combination with abiraterone and prednisone/prednisolone, met the co-primary endpoint of radiographic progression-free survival (rPFS).
Roche, the pharmaceutical giant, said a phase 3 study, evaluating its ipatasertib in combination with abiraterone and prednisone/prednisolone, met the co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer, but the other co-primary endpoint of rPFS in the overall study population was not met.
From a chartist's point of view, the short term consolidation started in May could be over as prices have landed on a key support at 320CHF and are posting a rebound. The breakout confirmation of the 20DMA is a bullish event. The daily Relative Strength Index (RSI, 14) is pushing above its declining trend line. The general up trend remains in place.
Readers may want to consider the potential for long positions above the horizontal support at 320CHF with 351CHF and 358CHF as targets. Alternatively, a break below 320CHF would invalidate the bullish trend and would call for a down move towards 298CHF.
Source: GAIN Capital, TradingView
StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.